Developer of cell therapy products designed to safely replace patients' diseased blood and immune system with a healthy
Developer of cell therapy products designed to safely replace patients' diseased blood and immune system with a healthy one.
Drug Discovery📍 Menlo Park, CAFounded 2015
Current Valuation
$1.2B
as of 2020-Q2
UNICORN
QL Price
$1.3B
+8% vs last round
QuantLogix's current estimate for Orca Bio, published 2026-09-27 — above the last disclosed round of $1.2B (2020-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.2B
2020-Q2
weight 0.01
Secondary market print
$1.3B
2026-06-27
weight 0.58
How this price has held up
No round has priced for Orca Bio since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Orca Bio, 2026-09-27 (8aa9727df6e2f5e3).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Orca Bio going public?
No. Orca Bio is private and has not filed to go public. There is no S-1 on file.
What is Orca Bio's valuation in 2026?
Orca Bio is valued at $1.2B as of 2020-Q2, set by its Series D ($192M, Jun 2020). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Orca Bio filed an S-1?
No public S-1 is on file for Orca Bio.
How much has Orca Bio raised?
Orca Bio has raised $325M in total, most recently a Series D of $192M in Jun 2020.
Is Orca Bio publicly traded — can you buy Orca Bio stock?
No. Orca Bio is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Orca Bio on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2015
HQ
Menlo Park, CA
Employees
336
Total Raised
$325M
Last Round
Series D — $192M (Jun 2020)
IPO Status
private
Fundraising Status
Series D · $192M · 6y 3mo ago
privateTotal raised $325M
Secondary Market
Implied price / share
$38
Last round price / share
$35.01
vs last round
+8.5%
Open interest
1
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$192M
Jun 2020
—
$1.2B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Orca Bio — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
-4% vs 2026-08
Open roles
45
via lever
Product-build share
40%
engineering, research, product, design
Trajectory
steady
balanced build + GTM — 40% builders vs 60% go-to-market/G&A — scaling both sides.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Clinical Research AssociateDirector/Head, PharmacovigilanceEngineer, Manufacturing Sciences & Technology (MSAT) (3rd Shift)Engineer, Packaging and LabelingGeneral Manager, Commercial Manufacturing FacilityManufacturing Process Lead (3rd Shift)
Counted from Orca Bio's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Health CareMedicalPharmaceutical
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2020-Q2. Refreshed quarterly.